Allergan Announces Marketing Authorization For TrueTear - Quick Facts

(RTTNews) - Allergan plc (AGN) announced it has been granted marketing authorization from the U.S. FDA for TrueTear Intranasal Tear Neurostimulator, the only FDA-cleared device developed to temporarily increase tear production during neurostimulation in adult patients.

TrueTear is a handheld stimulator with daily disposable tips that is inserted into the nasal cavity to induce the production of tears. The new advancement is an addition to Allergan's current eye care portfolio. Last May, Allergan announced positive results from two pivotal trials for TrueTear that showed an increase in tear production upon nasal neurostimulation in adults with aqueous tear deficiency.